📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-08 14:52
0 analysed today
FollowTelegram
0
Today
153,423
All-time analysed
44,082
Positive
6,813
Negative
93,584
Neutral
8,876
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Molbio Q1 FY27 Total Income Reaches ₹411.5 Cr; EBITDA Swings to ₹103.7 Cr
Molbio Diagnostics released its Q1 FY27 investor presentation following its recent listing on August 17, 2026. Total income surged to ₹411.5 crore compared to ₹100.5 crore in Q1 FY26, driven by higher Truenat test-kit volumes (6.2 million units vs 0.8 million units). EBITDA turned positive to ₹103.7 crore (25.2% margin) against an EBITDA loss of ₹14.5 crore in Q1 FY26, while PAT stood at ₹52.7 crore compared to a net loss of ₹23.9 crore. Performance also benefited from ₹57 crore of deferred export orders from Q4 FY26 recognized this quarter.
Confidence: HIGH
What changedMolbio published its detailed Q1 FY27 investor presentation post-listing, showing sharp year-on-year operational and profitability turnaround.
Why it mattersDemonstrates operating leverage as high-margin test-kit consumable consumption increases on its global base of 12,500+ installed Truenat devices.
Total Income (Q1 FY27): ₹411.5 CrEBITDA (Q1 FY27): ₹103.7 CrPAT (Q1 FY27): ₹52.7 CrDeferred Export Orders Recognized: ₹57 CrTest Kits Sold (Q1 FY27): 6.2 Mn units
📅 Short termMarket may view the sharp turnaround from losses positively, although management highlighted non-linear revenue seasonality and that Q1 benefited from ₹57 Cr of deferred Q4 FY26 export revenue.
📈 Long termWith capacity headroom in place (FY26 utilization at 42% for devices and 58% for test kits) and a pipeline of 34 assays across 22 diseases, the business is well-positioned for consumable-led margin expansion.
⚠ Risk flags
- Lumpy and non-linear quarterly revenue profile dependent on tender and export timing
- ₹57 Cr of Q1 FY27 revenue was a spillover from deferred Q4 FY26 orders due to Gulf geopolitical disruptions
Key Highlights
Q1 FY27 Total Income grew to ₹411.5 Cr vs ₹100.5 Cr in Q1 FY26
EBITDA swung to ₹103.7 Cr (25.2% margin) from a loss of ₹14.5 Cr in Q1 FY26
PAT turned positive at ₹52.7 Cr against a net loss of ₹23.9 Cr in Q1 FY26
Truenat test-kit volumes surged to 6.2 Mn units in Q1 FY27 from 0.8 Mn units in Q1 FY26
Results included ~₹57 Cr of deferred Q4 FY26 export orders recognized in Q1 FY27
👀 What to Watch
Track the sustainability of consumable test-kit sales and device rollouts without the one-off support of deferred export orders (₹57 crore). Also monitor the deployment of IPO proceeds into the Bengaluru R&D center and automation capex.
Molbio Q1 FY27 Total Income Reaches ₹411.48 Cr; PAT Turns Positive at ₹52.74 Cr
Molbio Diagnostics announced its Q1 FY27 results (its first after listing on August 17, 2026), posting Total Income of ₹411.48 Cr compared to ₹100.47 Cr in Q1 FY26. The company turned profitable with an EBITDA of ₹103.68 Cr (25.20% margin) vs an EBITDA loss of ₹14.50 Cr in Q1 FY26, and a PAT of ₹52.74 Cr vs a net loss of ₹23.94 Cr in Q1 FY26. Performance was driven by Truenat test-kit volume expansion to 6.24 Mn units (up from 0.79 Mn in Q1 FY26), alongside the recognition of ₹57 Cr in deferred export orders from Q4 FY26.
Confidence: HIGH
What changedMolbio turned profitable YoY in Q1 FY27 following its August 2026 listing, driven by a sharp rise in Truenat consumable sales.
Why it mattersDemonstrates strong operating leverage as the installed base of 12,500+ devices drives high-margin recurring test-kit consumption, with existing capacity headroom (58% test-kit utilization in FY26) limiting near-term capex needs.
Total Income (Q1 FY27): ₹411.48 CrEBITDA (Q1 FY27): ₹103.68 CrPAT (Q1 FY27): ₹52.74 CrTest-kits sold: 6.24 Mn UnitsDeferred Export Orders Recognized: ₹57 Cr
📅 Short termSentiment will be supported by the strong operational turnaround and swing to profitability in its debut quarterly earnings release.
📈 Long termStructural growth depends on expanding test-kit consumption per installed device, commercialization of the 34-assay pipeline across oncology/NCDs, and international regulatory approvals like CE-IVDR.
⚠ Risk flags
- Lumpy/non-linear quarterly revenue profile noted by management
- Geopolitical delays in international shipments (e.g., Gulf region order deferrals)
- High domestic revenue concentration (83.52% in Q1 FY27)
Key Highlights
Total Income surged to ₹411.48 Cr in Q1 FY27 vs ₹100.47 Cr in Q1 FY26
EBITDA turned positive to ₹103.68 Cr (25.20% margin) vs an EBITDA loss of ₹14.50 Cr in Q1 FY26
PAT stood at ₹52.74 Cr compared to a net loss of ₹23.94 Cr in Q1 FY26
Truenat test-kit sales reached 6.24 Mn units vs 0.79 Mn units in Q1 FY26
Deferred export orders of ~₹57 Cr from Q4 FY26 were recognized in Q1 FY27
👀 What to Watch
Track quarterly volume run-rates for Truenat kits to see if recurring non-linear revenues stabilize, and monitor the deployment of IPO proceeds toward the Bengaluru R&D and automation capex.
